대한갑상선학회 갑상선분화암 진료권고안; Part II. 갑상선분화암의 추적 2024open accessKorean Thyroid Association Guidelines on the Management of Differentiated Thyroid Cancers; Part II. Follow-up Surveillance after Initial Treatment 2024
- Authors
- 김미진; 방지인; 강호철; 김선욱; 나동규; 박영주; 서영덕; 송영신; 오소원; 이상우; 이은경; 이지예; 임동준; 정아리; 정윤재; 홍채문; 이민경; 김보현
- Issue Date
- May-2024
- Publisher
- 대한갑상선학회
- Keywords
- 갑상선분화암; 재발위험; 동적위험분류; 지속적위험분류; 갑상선자극호르몬 억제; 대한갑상선학회; 진료권고안; Differentiated thyroid cancer; Risk of recurrence; Dynamic risk assessment; TSH suppression; Korean Thyroid Association; Guideline
- Citation
- International Journal of Thyroidology, v.17, no.1, pp 115 - 146
- Pages
- 32
- Journal Title
- International Journal of Thyroidology
- Volume
- 17
- Number
- 1
- Start Page
- 115
- End Page
- 146
- URI
- https://scholarworks.bwise.kr/cau/handle/2019.sw.cau/74738
- DOI
- 10.11106/ijt.2024.17.1.115
- ISSN
- 2384-3799
2466-1899
- Abstract
- Based on the clinical, histopathological, and perioperative data of a patient with differentiated thyroid cancer (DTC), risk stratification based on their initial recurrence risk is a crucial follow-up (FU) strategy during the first 1–2 years after initial therapy. However, restratifiying the recurrence risk on the basis of current clinical data that becomes available after considering the response to treatment (ongoing risk stratification, ORS) provides a more accurate prediction of the status at the final FU and a more tailored management approach. Since the 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and DTC, the latest guidelines that include the National Comprehensive Cancer Network clinical practice and European Association for Medical Oncology guidelines have been updated to reflect several recent evidence in ORS and thyroid-stimulating hormone (TSH) suppression of DTC. The current clinical practice guideline was developed by extracting FU surveillance after the initial treatment section from the previous version of guidelines and updating it to reflect recent evidence. The current revised guideline includes recommendations for recent ORS, TSH target level based on risk stratification, FU tools for detection of recurrence and assessment of disease status, and long-term FU strategy for consideration of the disease status. These evidence-based recommendations are expected to avoid overtreatment and intensive FU of the majority of patients who will have a very good prognosis after the initial treatment of DTC patients, thereby ensuring that patients receive the most appropriate and effective treatment and FU options.
- Files in This Item
-
- Appears in
Collections - ETC > 1. Journal Articles
![qrcode](https://api.qrserver.com/v1/create-qr-code/?size=55x55&data=https://scholarworks.bwise.kr/cau/handle/2019.sw.cau/74738)
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.